Abstract. Intracellular tau aggregates composed of neurofibrillary tangles (NFTs) are a defining feature of Alzheimer's disease (AD). Increased expression of heme oxygenase-1 (HO-1) is a common phenomenon in AD. Interestingly, the spatial distribution of HO-1 expression is essentially identical to that of pathological accumulation of tau in AD. In this study, we developed a new transgenic mouse overexpressing HO-1, called CAG-HO-1 Tg mice, to explore the relationship between HO-1 and tau aggregation. In this model, we found that long-term overexpression of HO-1 significantly promoted tau aggregation in brain, by analyzing changes in morphology and insoluble tau expression levels. Moreover, our research provides the first in vivo evidence that HO-1 can enhance iron loading and tau (Ser199/202/396) phosphorylation in brains of transgenic mice. Cellular evidence indicates that HO-1 can induce the phosphorylation of tau through iron accumulation in Neuro2a cells stably transfected with HO-1. Our data suggest that long-term overexpression of HO-1 can promote tau aggregation. This mechanism involves excessive iron production mediated by HO-1 overexpression, which induces tau phosphorylation. Our results provide a potential pathway for the pathogenesis of tauopathies, which remains largely unknown.
INTRODUCTION
Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder and the leading cause of dementia [1] . AD is predominantly characterized by the presence of amyloid-␤(A␤) deposition, intracellu- * Correspondence to: Xu Gao, Tel.: +86 451 86671684; Fax: +86 451 8708 6131; E-mail: gaoxu6712@yahoo.com.cn and Weiming Zhao, Tel.: 86 451 86624142; E-mail: zhaowm@ems.hrbmu.edu.cn. lar neurofibrillary tangles (NFT), progressive loss of neurons, inflammatory responses, oxidative stress, and mitochondrial dysfunction. The NFTs observed in AD neurons consist of hyperphosphorylated, insoluble tau protein, resulting in tau aggregation [2] . Recent findings provide further support for the central role of tau in the pathogenesis of AD, demonstrating that tau phosphorylation and aggregation may be the final common pathway in this multifactorial disease. As a result, tau has become a diagnostic and therapeutic target for the disease [3] . By binding microtubules and promoting their polymerization, tau plays a crucial role in maintaining the physiological function of healthy neurons. Both direct toxic effects of aggregated tau and/or loss of axonal transport, due to transition of soluble tau into hyperphosphorylated and aggregated forms that are no longer capable of supporting axonal transport, have been proposed to contribute to AD [4] .
There is evidence indicating that heme oxygenase-1 (HO-1) is involved in AD. HO-1 is a 32 kDa protein that plays a key role in decomposing heme to biliverdin, freeing ferrous iron and carbon monoxide. Biliverdin reductase further degrades biliverdin to the bile pigment bilirubin [5] . HO-1 expression in normal, unstressed mammalian (rodent) brain is sparse and confined to scattered neuroglia, small populations of neurons in the cerebellum (Purkinje cells), thalamus, hypothalamus, brain stem, hippocampal dentate gyrus, and cerebral cortex [6] .
HO-1 is a stress protein induced in response to a variety of oxidative stressors. Oxidative stress, engendered by pro-inflammatory cytokines, amyloid burden, accumulation of tau in neurofibrillary tangles, and infidelity of electron transport in senescent mitochondria, may contribute to up-regulation of neural HO-1 in AD [7, 8] .
Using immunolabeling techniques, significant overexpression of HO-1 in brains derived from human with neuropathologically-proven AD relative to agematched controls with no history of neurological illness was found by Schipper et al. [9] . Similarly, western blots of protein extracts prepared from the temporal cortex and hippocampus from AD patients brains exhibited robust HO-1 expression compared to neurohistologically normal controls matched for age and post-mortem interval [9] . In fact, upregulation of HO-1 appears to be an early occurrence in AD brains and correlates with decreased cognitive function [10] .
HO-1 is upregulated in AD brain tissue and is associated with neurofibrillary tangles and senile plaque neuritis [11] . HO-1 immunoreactivity is greatly enhanced in neurons and astrocytes of the hippocampus and cerebral cortex of subjects with AD and co-localizes with senile plaques, NFTs and corpora amylacea [12] . The results of an mild cognitive impairment (MCI) study strongly suggest that glial HO-1 induction is a relatively early event in the pathogenesis of sporadic AD [10] .
Accordingly, we speculate that there is a correlation between HO-1 overexpression and AD. However, the function of HO-1 in the pathogenesis of AD remains unclear. Most studies on the role of HO-1 in AD were conducted in vitro. Because AD is a degenerative disease resulting from long-term effects, experiments in cultured cells might not faithfully recapitulate this process. As a result, we were interested in the long-term effects of HO-1 in vivo. For this reason, we created a HO-1 overexpressing transgenic mouse model to study its function in the pathogenesis of AD and the mechanisms involved in this process.
METHOD

Generation and selection of transgenic mice
Transgenic mice were generated by the standard pronuclear injection technique using C57BL/6 mice [13] . For construction of the transgene, mouse HO-1 cDNA was cloned into a pCAGG plasmid. Expression of mouse HO-1 cDNA was driven by the chicken ␤-actin promoter linked to a human cytomegalovirus immediate-early enhancer, followed by first exon and intron of chicken ␤-actin. Mouse HO-1 transcript, with its own stop codon and poly(A) signal, was followed by a rabbit ␤-globin poly(A) sequence. The mRNA transcript of the transgene therefore consisted of part of the first exon of chicken ␤-actin, which is transcribed but not translated, followed by mouse HO-1 cDNA.
All of the animals were genotyped by PCR amplification of DNA extracted from the tails of mice to assess the presence of the mouse HO-1 transgene. The region from the exon of the pCAGG vector to exon 1 of HO-1 was amplified with the following primers: 5  GCC TTC TTC TTT TTC CTA CAG CTC 3 and 5  GGC ATG TCG GGC TGT GGAC 3 . Experiments were performed in compliance with protocols approved by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Throughout the study period, animals were housed in a controlled environment (temperature 22 • C, humidity 45-55%, 12 h light/12 h dark schedule), and efforts were made to minimize discomfort and the number of animals used.
Transgene expression analysis
Transgene mRNA expression was analyzed by reverse transcription-coupled quantitative real-time PCR (qRT-PCR). Total RNA from the hippocampus of Tg and wt mice was isolated and retro-transcribed into cDNA using a Reverse Transcription System Kit (Promega), according to the manufacturer's protocol. For reverse transcription (RT), the reaction was incubated at 25 • C for 5 min, followed by a 15 min • HO-1 sense, 5 -GAAGAACTTTCAGAAGGG TCAG-3 ;
As an internal control, GAPDH primers were used for RNA template normalization. Fluorescent signals were normalized to an internal reference ( Rn), and the threshold cycle (Ct) was set within the exponential phase of the PCR. The relative gene expression was calculated by comparing cycle times for each target PCR. The target PCR Ct values were normalized by subtracting the GAPDH Ct value, which gives the Ct value. From this value, the relative expression levels between treatments can be calculated using the following equation: relative gene expression = 2 − ( Ct) .
Immunohistochemistry
Mice were weighed, overdosed with pentobarbital (200 mg/kg) and perfused with 25 ml of 0.9% normal saline solution. Brains were collected from the animals immediately following perfusion and immersion fixed in 4% paraformaldehyde for 24 h.
Coronal sections were stained using an immunohistochemistry (IHC) procedure. Tissue was permeabilized with PBS-T for 20 min and incubated in 0.3% hydrogen peroxide for 20 min to quench endogenous peroxidases. After washing, tissue was blocked with 5% normal goat serum (Invitrogen Canada, Toronto, ON) for 30 min and incubated overnight at 4 • C with the tau antibody in Table 1 . The following day, sections were washed and incubated with a biotin-binding secondary antibody (goat-anti-rabbit IgG, 1 : 100) for 20 min. Sections were washed, and staining was developed with 0.05% DAB (SigmaAldrich Canada, Oakville, ON) and 0.03% H 2 O 2 . After washing, sections were counterstained with hematoxylin, dehydrated in ascending ethanol concentrations, cleared with xylene, and coverslipped.
Stained sections were imaged using an Olympus bx51 microscope. Digital images were acquired using a Chemidoc-it hr410 imaging system (UVP, CA, USA).
Transmission electron microscopy
To determine the ultrastructural features of nerve cells in mouse brains, transmission electron microscopy (TEM) was performed in CAG-HO-1-L Tg mice and WT littermates at 14 months of age (n = 3). These mice were deeply anesthetized with approximately 50 mg/kg of sodium pentobarbital (i.p.) and sacrificed by decapitation. The cerebral cortex was removed and fixed in 3% glutaraldehyde for 2 h. The tissues were post-fixed in 1% osmium tetroxide for 60 min at 4 • C. After dehydration with graded acetone, the blocks were embedded in Epon-812 and polymerized at 60 • C for 72 h. Thin sections were cut and mounted on 200 mesh copper grids, stained with uranyl acetate and lead citrate and examined with a HITACHI electron microscope (H-7650).
Isolation of insoluble tau from mouse hippocampus and cortex
The tissue extracts are always a MIXTURE of hippocampus and cortex. Tissue was homogenized in 300 l buffer A [containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM NaVO4, 50 mM NaF with protease inhibitors (Roche Applied Science)] on ice for 30 min and centrifuged at 1000 ×g for 15 min at 4 • C. One percent Triton X-100 was added to supernatants, and samples were separated into soluble and insoluble fractions by centrifugation at 15000 ×g for 20 min. The supernatant, containing solution protein, was stored at −80 • C and used for western blotting. The precipitate, containing insoluble protein, was dissolved in 1% SDS, and stored at −80 • C for western blotting analysis [14] .
Western blotting
Cells and mouse tissues were lysed in RIPA buffer with protease inhibitors (Roche Applied Science). After incubation at 4 • C for 30 min, cell and tissues lysates were centrifuged at 12,000 rpm for 20 min at 4 • C. The supernatant was stored at −80 • C for western blotting analysis. Protein concentrations were measured using a BCA kit.
Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis (12% gel) and transferred to nitrocellulose membranes. Membranes were boiled for 10 min in PBS and blocked with 5% BSA in TBST (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.5% Tween-20) at room temperature for 3 h. Primary antibodies against HO-1 (Santa Cruz, sc10789, 1 : 4000), GAPDH (Cell Signaling, 14c10, 1 : 2000), tau phosphorylated at S199/S202 (Abcam, ab4864, 1 : 1000), tau phosphorylated at S396 (Abcam, ab30663, 1 : 1000), and tau5 (Miliprore, mab361) in Table 1 were applied overnight at 4 • C. After washing in TBST, the membranes were incubated with suitable secondary antibodies for 2 h at room temperature, visualized using an enhanced chemiluminescence substrate kit and exposed to film.
Stable transfection of cell lines
Mouse neuro2a cells (N2A) were grown in Minimum Essential Medium Eagle (MEME, SigmaAldrich, M0643) and 10% FBS (Gibco) with 5% CO 2 at 37 • C in an incubator.
Mouse HO-1 cDNA was cloned into a pcDNA3.1 plasmid to create the pcDNA3.1-HO-1 vector.
Cells were seeded one day before transfection with an initial seeding density of 2×105 cells in six-well plates. For stable transfection assays, the cells were subjected to drug selection (500 g/ml G-418 (Amresco)) 48 h after transfection with lipofectamine 2000 (Invitrogen Corporation, CA, USA) and pcDNA3.1 and pcDNA3.1-HO-1 vectors, according to the manufacturer's instructions. Distinct, antibioticresistant individual colonies appeared after two weeks and were handpicked using a micropipette, dissociated into small clumps of cells and transferred into one well in a 96-well culture dish. Cells were later transferred into a 24-well culture dish. The cells were then expanded in a six-well plate and continuously propagated in the presence of antibiotics. Later we found several stably transfected cell lines using PCR and western blotting. In some experiments, the cells were grown without drug selection.
Iron and DFO treatment
Iron was supplied to Neuro2a cells as iron citrate (Sigma, F3388), in a supplemental medium, at concentrations of 10 M, 20 M, 30 M, 60 M, or 100 M. For iron chelating experiments, DFO (deferoxamine mesylate, D533, Sigma) was applied to Neuro2a cells at 100 M, in a supplemental medium, four hours after iron treatment. Iron and iron-chelating treatments were performed within 24 h. Cells were then collected for analysis.
Iron assay
The non-heme iron content of tissue samples was measured as described previously [15] . A standard iron solution was made, which contained 0.1 mg of iron per ml. A 4% sodium pyrophosphate solution was prepared with iron-free distilled water. Trichloroacetic Acid (TCA) was redistilled, and a 50% stock solution was made with iron-free distilled water. This stock solution was diluted to a 25% aqueous solution for use. A 0.4% solution of a,a -bipyridine (J&K CHEMICA, 107095) was prepared in redistilled 0.005 N HCl, and a 2% solution of sodium ascorbate (Amresco, 0561-100) was prepared fresh daily in iron-free distilled water.
Two molar acetate buffer (pH 4.78) was prepared from reagent-grade sodium acetate and glacial acetic acid made with iron-free water.
Mice were deeply anesthetized and sacrificed by decapitation. Tissue was washed in iron-free water, blotted dry and weighed. Subsequently, tissue was homogenized in 5 ml centrifuge tubes, water was added to bring the volume to 3 ml, and the solutions were mixed. Aliquots (1 ml) of the homogenate were placed in 2 ml centrifuge tubes. Then 800 l of an extraction mixture (a 1 : 1 ratio of 25% TCA and 4% sodium pyrophosphate solutions) was added to each centrifuge tube. The tubes were placed in a boiling water bath for 15 min. Then the tubes were centrifuged at 2000 ×g for 20 min. The supernatant solution was filtered through a 0.45 m bacterial filter and collected into 5 ml centrifuge tubes. The sediment was resuspended, heated, centrifuged, and filtered as described above. After this second extraction, the filtrates were combined, and the volume was brought to 2 ml with iron-free water.
Three-hundred microliter aliquots of the filtrate, 100 l of sodium ascorbate, 100 l of a,a -bipyridine and 200 l of acetate buffer were added to the unknown samples. The same reagents were added to the blank sample (B1), except the a,a -bipyridine solution was replaced with 100 l of distilled water. A standard was prepared by substituting 100 l of an aqueous iron solution (5 g/ml), 100 l of sodium pyrophosphate and 100 l of trichloroacetic acid solution for the filtrate; the same reagents added to the unknown samples were then added to the standard. A standard blank (B2) was prepared in a similar manner to the standard, except that 100 l of distilled water was substituted for the iron solution. A reagent blank (B3) was made using 100 l of distilled water, 100 l of sodium ascorbate and 200 l of acetate buffer. All tubes were mixed and allowed to incubate at room temperature for 30 min. Then the optical density was measured in a spectrophotometer with the wavelength set at 520 nm.
The quantity of iron in each sample was calculated by the following formula: 
Statistical analysis
An independent samples t-test (SPSS 16.0) was used to calculate significant (p < 0.05) differences. Asterisks in the figures represent statistically significant differences. All of the assays were repeated at least three times; all of the histograms show the mean values ±S.E.M.
Result 1. Generation of CAG-HO-1 transgenic mice and transgene expression
CAG-HO-1 Tg mice were developed to express mouse HO-1 under the control of the CAG promoter (Fig. 1A) . Six founders were obtained, three of which transmitted the transgene in a Mendelian manner. One of the three lines expressed low levels of exogenous HO-1 (CAG-HO-1-L), and two of the three lines expressed high levels of exogenous HO-1 (CAG-HO-1-H). No exogenous HO-1 signals were found in samples from WT mice (Fig. 1B) . The total HO-1 mRNA expression (both exogenous and endogenous) was evaluated in mouse brain samples by qRT-PCR. Expression of HO-1 was significantly higher in brain samples from Tg mice. The expression level of HO-1 in CAG-HO-1-H (H) mice was approximately 5-fold higher than in CAG-HO-1-L (L) mice (Fig. 1C) .
As a consequence of transgene expression, the total HO-1 protein production detected in lysates from the brains of Tg animals was significantly increased compared to wide type littermates(WT). HO-1 expression in CAG-HO-1-L (L) mice was about 4-fold greater than WT, whereas expression in CAG-HO-1-H (H) mice was about 25-fold greater than in WT mice (Fig. 1D) .
Result 2. Immunohistochemical staining of tau and CAG-HO-1-L Tg mouse brain ultrastructure
Tau accumulation in the brains of 14-month-old low expression Tg mice (CAG-HO-1-L) was examined by immunohistochemistry, using a polyclonal antibody specific for total tau protein. lation of tau proteins in insoluble aggregates in large brain regions, with high expression in pyramidal neurons of the cerebral cortex and hippocampus (Fig. 2) . Because tau protein plays a crucial role in maintaining the structure and function of microtubules, we examined the ultrastructure of microtubules by electron microscopy. The structure of the microtubules was severely destroyed, as demonstrated by the twining and dissolving of microtubules in the cerebral cortex of Tg mice (Fig. 3) .
Result 3. The effect of HO-1 overexpression on insoluble tau in mouse brain
To further confirm the histological data, we examined the effects of Tg HO-1 on insoluble tau protein levels in the brains of HO-1 Tg mice. Insoluble tau was extracted from the hippocampus and cerebral cortex of both low and high expressing lines of mice at various ages. Total insoluble fractions were subjected to immunoblotting with a specific tau-5 antibody that recognizes all tau isoforms (Fig. 4A, B) . Compared to WT littermates, the insoluble tau in Tg mice showed the same developmental tendency in both low and high expressing lines. First, the insoluble tau decreased in CAG-HO-1-H (6 mo) and CAG-HO-1-L (9 mo) Tg mice compared to WT mice. Second, the levels of insoluble tau in CAG-HO-1-H (9 mo) and CAG-HO-1-L (12 mo) Tg mice rose until they were almost equal to the levels of tau expression in WT mice. Subsequently, the insoluble tau in CAG-HO-1-H (12 mo.) and CAG-HO-1-L (14 mo) Tg mice clearly increased relative to WT littermates (Fig. 4A, B) . The effect of long term HO-1 overexpression on the formation of insoluble tau in brain is ultimately inhibited at earlier stages of disease, while it is induced in later disease states (Fig. 4 C) .
Result 4. Tg HO-1 affects phosphorylation of tau in Neuro2a cells
As previously reported, phosphorylation is a key regulatory mechanism that disrupts the ability of tau to bind microtubules and promote their assembly [4] . As a result, we examined whether HO-1 would have any effect on the phosphorylation pattern of tau. We established two Neuro2a cell lines stably transfected with HO-1, expressing low levels of HO-1 (number 4) or high levels of HO-1 (number 1) (Fig. 5A) . In AD, tau is phosphorylated at multiple sites throughout its 441 amino acids, but some studies suggest that only specific phosphorylation sites, such as S396 or S202, are associated with neurodegeneration [16] . In this study, we chose to examine two phosphorylation sites of tau, Ser396 and Ser199/202. An siRNA assay using pLL3.7-shHO-1 was performed to verify the results in Neuro2a cell lines stably transfected with HO-1. The results showed that the phosphorylation state of p-tau (Ser396) and p-tau (Ser199/202) were significantly increased due to the overexpression of HO-1 (Fig. 5B) . Transfection with pLL3.7-shHO-1 was able to effectively reverse this phenotype (Fig. 5D) .
Result 5. Tg HO-1 affects protein phosphorylation of tau in mouse brain
We validated the effects of Tg HO-1 on the phosphorylation state of tau in mouse brain. Insoluble fractions from the hippocampus and cerebral cortex were extracted from mice of the same ages used in the previous experiments. Specific antibodies against ptau (ser396) and p-tau (ser199/202) were used in immunoblotting (Fig. 6A-D) . Compared to WT littermates, p-tau (ser396) and p-tau (ser199/202) of insoluble fractions from Tg mouse brains showed the same developmental tendency as insoluble total tau. Long term HO-1 overexpression has an induction effect on the formation of insoluble p-tau (ser396) and p-tau (ser199/202) in brain (Fig. 6E, F) .
Result 6. HO-1 overexpression may induce the phosphorylation of tau by enhancing iron loading in mouse brain
Iron is one of the metabolites of HO-1. It was reported that iron-mediated oxidative stress, perhaps in association with cell signaling disturbances, could promote increased phosphorylation of the microtubule-associated protein tau [17] . We found that the non-heme iron content of the basal nucleus was significantly increased in 14-month-old CAG-HO-1 Tg mice compared to WT littermates (Fig. 7) . Neuro2a cells were incubated with increasing concentrations of iron, ranging from 0 to 100 M. Twenty micromoles per liter of Fe efficiently promoted the phosphorylation state of p-tau(Ser199/202) and p-tau(Ser396) (Fig. 8A, C) . In Neuro2a cells stably transfected with HO-1, DFO was able to effectively reverse the induction of HO-1 phosphorylation of tau (Fig. 8B, D) . These results suggest that HO-1 overexpression may induce the phosphorylation of tau by enhancing iron loading in the mouse brain. 
DISCUSSION
We constructed a transgenic mouse that ubiquitously expresses mouse HO-1. The increased level of HO-1 in transgenic mice is comparable to AD patients according to the report on the expression of HO-1 in the AD brain by Schipper HM [9] . At approximately 14 months old, transgenic mice present with a tauopathy phenotype. As shown with light microscopy, many nerve cells in the hippocampus and cerebral cortex from 14-month-old CAG-HO-1-L Tg mice were strongly immunoreactive for tau. These morphological findings were also found at the biochemical level. Insoluble tau protein in the hippocampus and cerebral cortex of 12-month-old CAG-HO-1-H and 14-monthold CAG-HO-1-L transgenic mice was found to be greatly increased using western blotting. Additionally, in Neuro2a cells stably expressing HO-1, we found that HO-1 can induce the phosphorylation of tau, using antibodies of against tau (ser199/202) and tau (ser396). Moreover, this induction could be reverted by DFO, an iron chelating agent. These observations in Neuro2a cells were confirmed in CAG-HO-1 Tg mice. In 12-month-old CAG-HO-1-H and 14-month-old CAG-HO-1-L transgenic mice, insoluble phosphorylated tau (ser199/202) and tau (ser396) was increased in the hippocampus and cerebral cortex, and the concentration of iron in the basal nucleus was elevated, compared to age-matched controls. These results suggest that long-term overexpression of HO-1 can promote phosphorylation and aggregation of insoluble tau; the effect of HO-1 on tau phosphorylation may have been mediated by producing excess iron.
Human neuropathological surveys have reported a correlation between HO-1 and tauopathy. However, the mechanism by which HO-1 leads to tauopathy was not determined. A few in vitro studies have investigated this question. At the cellular level, some studies reported that HO-1 is able to inhibit tau expression [18] and trigger proteosome-mediated tau degradation [19] . However, the effect of long-term HO-1 overexpression in a whole organism may be different from its effect in cells. In this study, we demonstrated the relationship between HO-1 and tau aggregation in transgenic mice for the first time. Additionally, we found that HO-1 influenced tau phosphorylation at specific sites.
Among the features of the pathogenesis of AD, iron deposition in the brain has become a focus of research in recent years. Many studies have shown that iron can induce aggregation of hyperphosphorylated tau [20] . Iron-mediated oxidative stress, perhaps in association with cell signaling disturbances, promotes phosphorylation of microtubule-associated protein tau and expression of cell cycle proteins in post-mitotic neurons [17, [21] [22] [23] . Iron might play a role in the aggregation of tau and lead to the formation of NFTs in the AD brain. However, the mechanism of brain iron deposition remains unclear. Overexpression of human HO-1 in cultured rat astroglia promotes trapping of non-transferrin-bound 55Fe by the mitochondrial compartment [24] . In this study, we showed for the first time that overexpression of HO-1 can increase the concentration of brain iron in vivo. This observation offers a potential pathway for iron deposition in the brain and provides an explanation for the tauopathy phenotype formed in CAG-HO-1 Tg mice.
In contrast to older CAG-HO-1 Tg mice, the insoluble total tau and insoluble phosphorylated tau (ser199/202) and tau (ser396) from the hippocampus and cerebral cortex in younger transgenic mice (6-month-old CAG-HO-1-H and 9-month-old CAG-HO-1-L) were less than that found WT mice. This suggests that the effect of HO-1 overexpression on tau protein differs according to the length of HO-1 overexpression in vivo. At earlier stages, HO-1 overexpression inhibits tau aggregation, which has a protective effect. However, in later stages, HO-1 overexpression begins to facilitate tau aggregation, which is harmful. Whether HO-1 up-regulation in the diseased nervous system plays a cytoprotective [18, 25] or neurodegenerative role [24, 26] is currently under debate. The different effects of HO-1 at distinct stages of pathogenesis in our study may account for the disparate data regarding the role of HO-1 induction in brain aging and disease. We suppose that the cumulative effect of HO-1 may come from its metabolites, leading to different results at different stages of disease in CAG-HO-1 Tg mice.
There is evidence indicating that the overexpression of HO-1 reduces the neurotoxin-induced cell death in transgenic mice and neuronal cultures, suggesting a cytoprotective role of HO-1. For example, HO-1 overexpression triggers proteosome-mediated protein degradation and prevents intracellular accumulation of abnormal protein aggregates and inclusions in human neuroblastoma M17 cells [19] . HO-1 may also be involved in neuroprotection in traumatic animal models [27, 28] and in excitotoxic brain damage and spinal cord injury [29] . It is possible that the protective role of HO-1 occurs by virtue of the anti-inflammatory and antioxidant capacities of CO, biliverdin and bilirubin, a metabolite of biliverdin [30] [31] [32] [33] [34] [35] [36] . Up-regulation of HO-1 may provide cytoprotection by promoting the catabolism of the prooxidant heme to the radicalscavenging bile pigments, biliverdin and bilirubin. Bilirubin is an endogenous antioxidant that can remove oxygen radicals [35] . CO and bilirubin displayed antiapoptotic function in some studies [37, 38] . Additionally, intracellular iron is the principal regulator of ferritin synthesis. Iron released by HO-1 induces upregulation of ferritin synthesis, which protects the brain from oxidative damage [39] . In addition, some in vitro studies support our results in younger CAG-HO-1 Tg mice. In one study, Smith and colleagues [18] showed that tau expression decreased in a neuroblastoma cell line transfected with human HO-1 cDNA. Perhaps, at an earlier stage, HO-1 overexpression inhibits tau aggregation and mainly plays a protective role. In contrast, there is evidence indicating that the overexpression of HO-1 plays a detrimental role. For example, astroglia cells overexpressing HO-1 predispose co-cultured PC12 cells to oxidative injury [40] . Moreover, dynamic SIMS revealed intense foci of elemental iron within HMOX1-transfected cells, which co-localized with organelles identified as pathological mitochondria on the basis of size, shape, number, investing membranes, perinuclear deployment, and oxygen-labeling. These cytopathological changes indicate that HO-1 overexpression in astrocytes promotes the classical ultrastructural features of macroautophagy, a process that has been demonstrated in the senescent and AD human brains [41] . It is possible that long-term overexpression of HO-1 might cause overproduction of metabolites. When the accumulation of metabolic products exceeds a certain threshold, these metabolites may show a toxic effect. For example, although experimental and epidemiological evidence suggests that bilirubin may serve as a physiological antioxidant [42, 43] , abnormal accumulation of bilirubin may cause neurotoxicity [44] . Under certain circumstances, heme-derived iron and CO may exacerbate oxidative substrate damage by facilitating the production of reactive oxygen species within the mitochondria and other subcellular compartments [45] [46] [47] . In addition, "the iron hypothesis" deserves special attention as it is tightly linked to aging and various neurodegenerative diseases [46] [47] [48] . There is increasing evidence that iron is involved in the mechanisms that underlie many neurodegenerative diseases. High concentrations of reactive iron can increase oxidativestress via the Fenton reaction, inducing neuronal vulnerability, and iron accumulation might increase the toxicity of environmental or endogenous toxins, causing diseases like AD and PD [48] . Furthermore, in this study, we found long-term overexpression of HO-1 increased the brain iron concentrations in the basal nucleus of CAG-HO-1 Tg mice. Therefore, in later stages, HO-1 may exacerbate neuropathology by long-term overexpression.
These data suggest a central role of long-term HO-1 overexpression in the pathogenesis of AD. However, we have not discussed whether long-term HO-1 overexpression occurs in the pathogenesis of AD in humans. The free radical hypothesis of AD could provide a reasonable explanation for promoting HO-1 overexpression in AD. The free radical hypothesis of AD posits that the age-related accumulation of free radicals and reactive oxygen species damage the major components of cells, including the nucleus, mitochondrial DNA, membranes, and cytoplasmic protein, which results in oxidative stress. Oxidative stress, as an early event, is involved in the pathogenesis of most neurodegenerative disorders, including AD [49] [50] [51] . At early stages, HO-1, which is a very sensitive marker of oxidative stress, would be induced by the free radicals and oxidative stress produced by aging and would display protective functions against oxidation, inflammation and apoptosis. Age-related oxidative stress has been amply documented in AD-affected brain tissues and may be responsible for induction of HO-1 in patients with AD [9] . As a result, HO-1 might be continually activated, resulting in long-term overexpression. Numbers of HO-1-immunoreactive neuroglia progressively increase in human cortical and subcortical brain regions with advancing age [52] . Thus, long-term HO-1 overexpression is likely to occur during aging and inflammation and following pro-oxidant stimuli (heme, Th1 cytokines, A␤, H 2 O 2 , dopamine, hyperoxia, UV light, heavy metals, prostaglandins, nitric oxide [53] [54] [55] ), which are involved in AD and promote the generation and development of AD.
Circulating HO-1/HOS has served as a biomarker for the diagnosis of mild cognitive impairment and AD [56] . Of the 15 proteins found to be significantly altered in sera from patients with mild AD compared to normal patients or patients with of mild cognitive impairment, 14 contained HO-1, biliverdin reductase A or biliverdin reductase B. This strongly implicates HO-1 as a potential biomarker for AD [57] .
Pharmacological modulation of HO-1 levels in the brain, within therapeutic limits, shows promising results in models of AD, Parkinson's disease and other infectious diseases, such as malaria [39] . A more complete understanding of how HO-1 is involved in the pathogenesis of neurological diseases will be essential to develop therapeutic approaches to treat these diseases. In the following years, we will witness the description of chemicals, drugs and/or dietary products that cross the blood brain barrier efficiently, modulate HO-1 expression and achieve neuroprotective and anti-inflammatory effects in vivo [39] .
